---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-24-000957"
form_type: "8-K"
ticker: "VANI"
cik: "0001266806"
company_name: "Vivani Medical, Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T01:58:17.726276+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vivani Medical Q1 net loss $6.0M, cash $31.0M; NPM-115 IND on track for H2 2024

## Summary
- Net loss of $6.0M in Q1 2024 vs $6.3M in Q1 2023; cash $31.0M at March 31, 2024, up from $22.0M.
- Completed $15M registered direct offering in March 2024, extending cash runway into H2 2025.
- NPM-115 IND submission on track for H2 2024; first-in-human trial planned after regulatory clearance.
- Positive preclinical data: NPM-115 showed ~20% weight loss in mice, comparable to semaglutide.
- Appointed Daniel Bradbury to Board; he led Amylin's development of first once-weekly GLP-1 Bydureon.

## SEC filing metadata
- accession: 0001753926-24-000957
- form_type: 8-K
- ticker: VANI
- cik: 0001266806
- company_name: Vivani Medical, Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1266806/000175392624000957/0001753926-24-000957-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1266806/000175392624000957/g084237_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-24-000957
- JSON: https://secwatch.observer/filing/0001753926-24-000957.json
- Plain text: https://secwatch.observer/filing/0001753926-24-000957.txt

## Key facts
- Earnings Releases
  Vivani Medical, Inc. reported first quarter ended March 31, 2024 results: net income Net loss during the three months ended March 31, 2024 was $6.0 million.
  - Period: first quarter ended March 31, 2024
  - Net income: Net loss during the three months ended March 31, 2024 was $6.0 million
  - Result: reported results
  source text: Net loss during the three months ended March 31, 2024 was $6.0 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1266806/000175392624000957/0001753926-24-000957-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.